Neurocosmetic Actives

Not a single ingredient but a mechanism-of-action category — actives that engage the skin's intrinsic neuroendocrine system (the 'skin-brain axis'). Keratinocytes, melanocytes, fibroblasts, and cutaneous immune cells locally synthesise neurotransmitters (serotonin, dopamine, GABA, β-endorphins) and express receptors for substance P, CGRP, and corticotropin-releasing hormone. Neurocosmetics target this circuitry — neuropeptides (Argireline-class, Leuphasyl) modulate neuromuscular signalling; substance-P antagonists (Gatuline Relaxer from Malus sylvestris) blunt neurogenic inflammation; β-endorphin-mimetic peptides reduce stress-driven cortisol release at the cutaneous level. Ashwagandha and passionflower extracts contribute supporting GABAergic and anti-stress activity.

Variable by active (typically 1–10% of the named neurocosmetic in finished formulation)

Key actives: neuropeptides (Argireline, Leuphasyl), ashwagandha, passionflower extract, Gatuline Relaxer (Malus sylvestris), and fermented neuroactive botanicals (licorice, turmeric).

'Skin-brain axis' is now peer-reviewed science but also a marketing buzz-phrase — look for named actives with mechanism, not vibes.

The 'cortisol-lowering cream' headline is the persistent overreach — the skin-brain axis is real, but a topical cream rarely modulates systemic cortisol in any clinically meaningful way. Marketing routinely conflates 'engages the skin's nervous system' with 'fixes stress', which is a category error. Specific neuropeptides deserve their own evaluation; 'neurocosmetic' as an umbrella term is largely a marketing concept.

The 2024–2026 category emerging as the heir to 'wellness skincare' — pitched at the chronic-stress consumer with cortisol-fatigued skin. Real value sits in the underlying named actives (most of which have their own slugs); the category-level positioning oversells what is largely a relabelling of established peptide and adaptogen chemistry.